

# ForPatients

by Roche

Small Cell Lung Cancer Small Cell Lung Carcinoma

## Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer (SKYSCRAPER-02C)

**Trial Status**

Active, not recruiting

**Trial Runs In**

1 Countries

**Trial Identifier**

NCT04665856 YO42373

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

The purpose of this multicenter study in China is to evaluate the safety and efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with untreated extensive-stage small cell lung cancer.

**Hoffmann-La Roche**

Sponsor

**Phase 3**

Phase

---

**NCT04665856 YO42373**

Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**

All

**Age**

>=18 Years

**Healthy Volunteers**

No

---